From Manhattan to the Alps: HCC unlocked

An evening with Prof. Ghassan K. Abou-Alfa and Swiss experts on (evolving) treatment strategies in HCC

www.medtoday.ch

November 24, 2026
18:30 – 20:00
Welle 7, Bern

Credits requested
SGC/SSC, SGG/SSG, SGMO, SGAIM, SSVIR

Program 24.11.2026

18:30 **Welcome and introduction**
Dre. Antonia Digklia, Dr. med. Guido Pesola

18:35 **Keynote: The HCC landscape in 2026 – from early to advanced disease**
Prof. Ghassan K. Abou-Alfa, MD, JD, MBA, PhD (hc)

19:00 **Early HCC: resection, transplantation, ablation in the era of (neo)adjuvant therapy**
Prof. Dr. med. Anja Lachenmayer

19:20 **Intermediate HCC: TACE/TARE, combining locoregional and systemic therapy, when to switch**
Dr. med. Alexis Ricoeur

19:40 **Advanced HCC: first- and second-line systemic therapy and sequencing**
Dre. Antonia Digklia, Dr. med. Guido Pesola

19:55 **Take-home messages and closing**
Dre. Antonia Digklia, Dr. med. Guido Pesola

20:00 **Apéro**

Dear Colleagues,

We are pleased to welcome Prof. Ghassan K. Abou-Alfa, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, to Switzerland. Prof. Abou-Alfa specialises in hepatocellular carcinoma (HCC) and other hepatobiliary and pancreatic cancers, and leads several international clinical trials in the field. On this occasion, we are organising a 90-minute, CME-accredited, multi-sponsored scientific seminar on HCC.

Around 820 people are diagnosed with liver cancer in Switzerland each year, and metabolic fatty liver disease is becoming an increasingly important cause. At the same time, treatment is changing fast: immunotherapy-based combinations are now standard in advanced disease and are moving into earlier stages, including in combination with locoregional therapies such as TACE. Applying these advances in Swiss practice raises practical questions about patient selection, treatment sequencing and preserving liver function.

The seminar covers the full disease continuum, from early to intermediate and advanced HCC. After a keynote by Prof. Abou-Alfa, Swiss experts will present case-based sessions, each followed by an interactive panel discussion.

This event is financially supported by the following companies

Main Sponsor

AstraZeneca

Co-Sponsor

Eisai

Register now!

medtoday.ch/events/hcc2026

National Experts



Dre. Antonia Digklia
CHUV



Prof. Dr. med. Anja Lachenmayer
Inselspital Bern



Dr. med. Guido Pesola
Oncologia medica, IOSI-EOC



Dr. med. Alexis Ricoeur
HUG

International Expert



Ghassan K. Abou-Alfa, MD, JD, MBA, PhD (hc)
Memorial Sloan Kettering Cancer Center,
New York, USA

med·today

medtoday Switzerland c/o PlayToKnow AG
Alte Landstrasse 55, 8802 Kilchberg | info@medtoday.ch